News coverage about XOMA Corporation (NASDAQ:XOMA) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. XOMA Corporation earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.5741243684929 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- XOMA Corporation (XOMA) (finance.yahoo.com)
- XOMA to Present at the Cantor Fitzgerald Global Healthcare Conference (feeds.benzinga.com)
- XOMA Out-License Model Catching Waves – Seeking Alpha (seekingalpha.com)
- Zacks Investment Research Downgrades XOMA Corporation (XOMA) to Sell (americanbankingnews.com)
- XOMA : Earns $3 Million Milestone Payment from its License Agreement with Nanotherapeutics (4-traders.com)
Several analysts have commented on the company. Zacks Investment Research cut XOMA Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, August 15th. Wedbush restated a “hold” rating on shares of XOMA Corporation in a report on Monday, August 14th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of XOMA Corporation in a report on Thursday, August 10th. Finally, ValuEngine upgraded XOMA Corporation from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 12th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. XOMA Corporation currently has a consensus rating of “Hold” and an average target price of $14.00.
Shares of XOMA Corporation (NASDAQ XOMA) traded down 1.78% during mid-day trading on Tuesday, hitting $18.75. The stock had a trading volume of 28,737 shares. The company has a 50-day moving average of $11.13 and a 200 day moving average of $7.76. XOMA Corporation has a one year low of $3.96 and a one year high of $20.40. The firm’s market cap is $142.46 million.
About XOMA Corporation
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.